Fate Therapeutics Inc. (NASDAQ:FATE) shares, rose in value on Thursday, 05/25/23, with the stock price down by -5.62% to the previous day’s close as strong demand from buyers drove the stock to $5.04.
Actively observing the price movement in the last trading, the stock closed the session at $5.34, falling within a range of $4.99 and $5.34. The value of beta (5-year monthly) was 1.49. Referring to stock’s 52-week performance, its high was $37.13, and the low was $4.02. On the whole, FATE has fluctuated by -13.40% over the past month.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
With the market capitalization of Fate Therapeutics Inc. currently standing at about $486.91 million, investors are eagerly awaiting this quarter’s results, scheduled for Aug 01, 2023 – Aug 07, 2023. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.6, which is expected to increase to -$0.31 for fiscal year -$1.91 and then to about -$2.02 by fiscal year 2024. Data indicates that the EPS growth is expected to be 34.40% in 2024, while the next year’s EPS growth is forecast to be -5.80%.
Analysts have estimated the company’s revenue for the quarter at $5.53 million, with a low estimate of $500k and a high estimate of $15.6 million. According to the average forecast, sales growth in current quarter could jump down -70.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2024, the company’s y-o-y revenues would reach $65.01 million, representing a decrease of -32.50% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that FATE’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 100% Sell while long term indicators on average have been pointing out that it is a 100% Sell.
23 analyst(s) have assigned their ratings of the stock’s forecast evaluation on a scale of 1.00-5.00 to indicate a strong buy to a strong sell recommendation. The stock is rated as a Hold by 14 analyst(s), 6 recommend it as a Buy and 1 called the FATE stock Overweight. In the meantime, 1 analyst(s) believe the stock as Underweight and 1 think it is a Sell. Thus, investors eager to increase their holdings of the company’s stock will have an opportunity to do so as the average rating for the stock is Hold.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of FATE currently trading nearly -8.32% and -10.60% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.89, while the 7-day volatility ratio is showing 6.06% which for the 30-day chart, stands at 7.79%. Furthermore, Fate Therapeutics Inc. (FATE)’s beta value is 1.50, and its average true range (ATR) is 0.39. The company’s stock has been forecasted to trade at an average price of $8.16 over the course of the next 52 weeks, with a low of $4.00 and a high of $16.00. Based on these price targets, the low is 20.63% off current price, whereas the price has to move -217.46% to reach the yearly target high. Additionally, analysts’ median price of $7.00 is likely to be welcomed by investors because it represents a decrease of -38.89% from the current levels.
A comparison of Fate Therapeutics Inc. (FATE) with its peers suggests the former has fared considerably weaker in the market. FATE showed an intraday change of -5.62% in last session, and over the past year, it shrunk by -76.16%%. In comparison, Ionis Pharmaceuticals Inc. (IONS) has moved lower at -5.11% on the day and was up 5.55% over the past 12 months. On the other hand, the price of Neurocrine Biosciences Inc. (NBIX) has fallen -0.46% on the day. The stock, however, is off 8.96% from where it was a year ago. Additionally, there is a loss of -1.42% for Becton Dickinson and Company (BDX) in last trading while the stock has seen an overall depriciation of -6.09%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it gained 0.88%. Meanwhile, the Dow Jones Industrial Slipped by -0.11%.
Data on historical trading for Fate Therapeutics Inc. (NASDAQ:FATE) indicates that the trading volumes over the past 10 days have averaged 1.97 million and over the past 3 months, they’ve averaged 2.69 million. According to company’s latest data on outstanding shares, there are 98.06 million shares outstanding.
Nearly 1.00% of Fate Therapeutics Inc.’s shares belong to company insiders and institutional investors own 106.35% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 29.13 million shares as on May 14, 2023, resulting in a short ratio of 12.45. According to the data, the short interest in Fate Therapeutics Inc. (FATE) stood at 29.61% of shares outstanding as of May 14, 2023; the number of short shares registered in Apr 13, 2023 reached 26.92 million. The stock has fallen by -50.05% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the FATE stock heading into the next quarter.
